Quercetin Notes on ER+ cancers and COMT

Quercetin is a dual-action hormone modulator with dose-dependent effects on aromatase, estrogen pathways, and COMT activity

Contents Menu

Part 1

• Quercetin and Estrogenic Activity

• Genetic Polymorphisms (SNPs) and Estrogen Metabolism

• The Role of COMT

• Why People with Certain SNPs and ER+ Cancer Should Be Cautious

• Summary Table: Key Considerations

• Practical Guidance
  

Part 2

• Quercetin's Role As A Natural Aromatase Inhibitor

• Key Evidence

• Strength as an AI

• Source 1: Scientific Reports (2021)

• Source 2: Journal of Research in Pharmacy

• Source 3: PMC (Natural Products as Aromatase Inhibitors)

• Source 4: Journal of Research in Pharmacy

• Source 5: PMC (Breast Cancer-Associated Natural Products)

• Source 6: Combinatorial Chemistry & High Throughput Screening (2024 Review)

• Key Consensus Across Studies

Overview: Quercetin and Estrogenic Activity

Quercetin is a plant-derived flavonoid often classified as a phytoestrogen, meaning it can interact with estrogen receptors (ERs) and influence estrogen signalling in the body 1 2 3. Studies show that quercetin can exert both estrogenic (mimicking estrogenic effects) and anti-estrogenic effects, depending on the dose, tissue, and context. 4 3 It has a higher binding affinity for ERβ than ERα, but at sufficiently high concentrations, it can promote cell proliferation through estrogenic pathways.

Clinicians emphasise dose-dependency and therapeutic thresholds (1,000 mg twice per day) to avoid underdosing, which might support ER+ cancers rather than work against them.

Context matters with Quercetin

Quercetin and Estrogen Receptor-Positive (ER+) Cancers

• Estrogenic and Anti-Estrogenic Effects: In breast cancer models, quercetin does not directly initiate tumour formation but can accelerate the growth of tumours in the presence of estrogen (E2), suggesting it may potentiate estrogen-driven cancer progression1 3.

• Cell Line Studies: In ER+ breast cancer cells (like MCF-7), quercetin can interfere with estrogen-induced gene expression and cell proliferation. Some studies suggest that quercetin acts more as an anti-estrogen, inhibiting cell growth, while others show that it can enhance estrogen’s effects, depending on the context and concentration.

• Combination with Therapies: Quercetin at low concentrations may inhibit the effectiveness of anti-estrogen therapies, such as tamoxifen; however, at higher concentrations (1000 mg twice daily with bromelian to increase absorption), it may enhance apoptosis (cell death) in cancer cells.

Genetic Polymorphisms (SNPs) and Estrogen Metabolism

The Role of COMT

• COMT Enzyme: Catechol-O-methyltransferase (COMT) is a key enzyme that detoxifies catechol estrogens, converting them into less estrogenic and less genotoxic forms.

• SNPs in COMT: Certain single-nucleotide polymorphisms (SNPs) in the COMT gene, such as the common Val158Met variant, reduce enzyme activity. Individuals with low-activity COMT variants have a higher risk of accumulating estrogen metabolites that can damage DNA and increase cancer risk.

• Quercetin and COMT: Quercetin is known to inhibit COMT activity in breast tissue, which may further reduce the detoxification of estrogen metabolites, especially in individuals already genetically predisposed to low COMT activity 1 9. This could result in prolonged exposure to carcinogenic estrogen metabolites and increased oxidative stress in breast tissue.

Why People with Certain SNPs and ER+ Cancer Should Be Cautious

• Increased Risk: If someone has ER+ cancer and carries SNPs that reduce COMT activity, quercetin supplementation could theoretically increase their risk by both mimicking estrogen and impairing the detoxification of harmful estrogen metabolites.

• Personalised Considerations: The impact of quercetin will depend on the individual's genetic background (especially COMT and other estrogen-metabolising enzymes), their hormonal status, and their cancer subtype.

• Clinical Evidence: While animal and cell studies provide valuable mechanistic insights, clinical data are currently limited. However, the evidence suggests that caution is warranted, particularly for individuals with ER+ cancers and known COMT or related SNPs.

Summary Table: Key Considerations

Practical Guidance

• Genetic Testing: Those with ER+ cancers may benefit from genetic testing for COMT and other estrogen-metabolising SNPs before considering quercetin supplements.

• Medical Supervision: Always consult with an oncology or genetics-informed healthcare provider before starting quercetin, especially if you have ER+ cancer or known SNPs affecting estrogen metabolism.

• Balancing Risks and Benefits: A minimum dose of 1,000 mg twice daily should be considered to avoid underdosing. How will that impact metabolism of other supplements?

In menopause?

Quercetin's Role As A Natural Aromatase Inhibitor

Quercetin's role as a natural aromatase inhibitor is robustly validated by peer-reviewed research, with specific mechanisms directly relevant to breast cancer, more on that below.

Important COMT SNP Considerations Apply Once Again:
While quercetin is a potent natural AI, its inhibition of catechol-O-methyltransferase (COMT) may be counterproductive in individuals with COMT single-nucleotide polymorphisms (SNPs) (e.g., Val158Met). These SNPs already reduce COMT enzyme activity, and quercetin further impairs estrogen metabolite detoxification. This can lead to:

• Accumulation of carcinogenic estrogen metabolites (e.g., 4-OH catechols).

• Increased oxidative stress and DNA damage in hormone-sensitive tissues.

• Potentially accelerated ER+ cancer progression despite AI effects..

Clinical Implications:
For patients with COMT SNPs, quercetin’s AI benefits may be offset by its estrogen-metabolism disruption. Genetic testing is advised before therapeutic use. If SNPs are present, alternative AIs (e.g., pharmaceutical AIs + non-COMT-inhibiting botanicals, such as white button mushrooms) are preferable. 

Key Evidence

1. COMT Inhibition Mechanism:
   Quercetin directly inhibits COMT, slowing detoxification of genotoxic estrogen metabolites. This is especially risky for those with pre-existing COMT SNPs, which reduce enzyme activity by 40–75%1.

2. ER+ Cancer Risk:
   In ER+ cancer models, quercetin’s COMT inhibition exacerbates the accumulation of DNA-damaging estrogen metabolites (e.g., 3,4-quinones), thereby increasing the risk of tumour progression13.

3. Dose Dependency:
   While high-dose quercetin (≥1,000 mg BID) exhibits anti-estrogenic effects, low/moderate doses may exert pro-estrogenic activity in SNP carriers.

Quercetin’s strength as an AI is well-established, but its COMT-inhibiting properties introduce significant caveats for individuals who are genetically susceptible. Always contextualise its use with COMT SNP status to avoid unintended harm in ER+ cancer contexts.

Strength as an AI

• Comparative potency: Among natural compounds, quercetin is one of the strongest AIs, though less potent than synthetic AIs (e.g., letrozole)

• Synergy with pharmaceuticals: Enhances apoptosis when combined with drugs like letrozole, indicating complementary anticancer effects. 

Below are verbatim quotes from each source confirming its efficacy:

Source 1: Scientific Reports (2021)

"Naringenin, naringin and quercetin demonstrated in vitro inhibitory potential against the aromatase enzyme along with anticancer potential in vivo, as evidenced by decreased tumour volumes. Reduction in aromatase levels in solid tumours was also observed in treated groups."
This study confirms quercetin's direct inhibition of aromatase and tumor suppression in breast cancer models.

Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer
Scientific Reports https://www.nature.com/articles/s41598-021-86599-z

Source 2: Journal of Research in Pharmacy

"quercetin (p<0.01) significantly inhibited [aromatase] activity at 100 µM" and "quercetin both have strong aromatase inhibitory effects among the flavonoids" .
The recombinant protein assay demonstrates quercetin's dose-dependent inhibition of the enzyme.

Inhibitory Aromatase Effects of Flavonoids from Ginkgo Biloba Extracts on Estrogen Biosynthesis https://journal.waocp.org/article_31412_a1688bd466e6a8054c10d001ad198e02.pdf

Source 3: PMC (Natural Products as Aromatase Inhibitors)

"Quercetin was found to inhibit human aromatase activity in placental microsomes".
This mechanistic evidence shows that quercetin directly targets aromatase activity. 

Natural Products as Aromatase Inhibitors - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC3074486/

Source 4: Journal of Research in Pharmacy

"Results from the study showed that letrozole and quercetin combination inhibited cell growth in MCF-7 and MDA-MB-231 cells and induced mitochondrial apoptosis".
Quercetin enhances conventional therapy by suppressing estrogen-driven cancer proliferation.

Anticancer effect of the letrozole-quercetin combination mediated by FOXOs and estrogen receptors in breast cancer cells.
https://jrespharm.com/pdf.php?id=903

Source 5: PMC (Breast Cancer-Associated Natural Products)

"Quercetin was found to inhibit human aromatase activity in placental microsomes" and "a decrease in the enzyme activity was observed at higher concentrations" .
Reinforces dose-dependent aromatase suppression, critical for therapeutic dosing.

Potential utility of natural products as regulators of breast cancer-associated aromatase promoters - PMC

https://pmc.ncbi.nlm.nih.gov/articles/PMC3142499/

Source 6: Combinatorial Chemistry & High Throughput Screening (2024 Review)

"Natural compounds such as ... quercetin ... have been investigated for their capacity to inhibit aromatase activity and lower estrogen levels" 

Review on Natural Agents as Aromatase Inhibitors: Management of Breast Cancer - PubMed https://pubmed.ncbi.nlm.nih.gov/37861041/

Related pages

• ER-Positive / HER2-Negative

• HER2-Positive

• COMT Status and Tamoxifen

• AI Resistance and the 4-OHE1/E2 Pathway